Current Study of Medicinal Chemistry for Treating Spinal Tuberculosis

Title:Current Study of Medicinal Chemistry for Treating Spinal Tuberculosis

Volume: 28 Issue: 25

Author(s): Biao Wang, Yuhang Wang and Dingjun Hao*

Affiliation:

• Department of Spine Surgery, Honghui Hospital, Xi’an Jiaotong University, Xi’an,China

Keywords: Tuberculosis, spinal, medicine, inflammation, diagnosis, treatment.

Abstract: Tuberculosis, caused by Mycobacterium tuberculosis, is one of the oldest diseases in the world and is one of the top ten causes of death in the world, ranking first mortality in infectious diseases, far beyond the frightening disease AIDS. Besides that, spinal tuberculosis is the most common form of extrapulmonary tuberculosis, accounting for approximately 1 to 3% of all tuberculosis cases, and accounting for 50% of musculoskeletal infections. However, the drug-resistant situation of spinal tuberculosis is still challenging world wide. This situation directly leads that spinal tuberculosis has a high disability rate and is difficult to treat, which causes a heavy burden to patients, families and society. Therefore, it has been one of the focuses of tuberculosis researchers and spine doctors. Considering that, in this review, we aim to overview the current studies that focused on the novel understanding of current spinal tuberculosis medicine usage and extensive explorations for treating this severe disease.

Cite this article as:

Wang Biao , Wang Yuhang and Hao Dingjun *, Current Study of Medicinal Chemistry for Treating Spinal Tuberculosis, Current Medicinal Chemistry 2021; 28 (25) . https://dx.doi.org/10.2174/0929867328666201222125225